LY 2452473/tadalafil

Drug Profile

LY 2452473/tadalafil

Alternative Names: LY 900010; LY2452473/tadalafil; tadalafil/LY 2452473

Latest Information Update: 27 Apr 2012

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Carbolines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 18 Apr 2012 Discontinued - Phase-II for Erectile dysfunction in USA (PO)
  • 30 Nov 2011 Eli Lilly completes a phase II trial in Erectile dysfunction in USA (NCT01160289)
  • 12 Sep 2011 Eli Lilly completes a phase I trial in Healthy volunteers in US (NCT01401543)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top